Epizyme Inc.

6.96-0.1200-1.69%Vol 495.79K1Y Perf -50.71%
Jul 23rd, 2021 16:00 DELAYED
BID6.95 ASK7.15
Open7.06 Previous Close7.08
Pre-Market- After-Market6.96
 - -  - -%
Target Price
18.50 
Analyst Rating
Moderate Buy 1.56
Potential %
165.81 
Finscreener Ranking
★★★     49.14
Insiders Trans % 3/6/12 mo.
-/-60/-53 
Value Ranking
     40.10
Insiders Value % 3/6/12 mo.
-/21/21 
Growth Ranking
★★★     54.11
Insiders Shares Cnt. % 3/6/12 mo.
-/32/32 
Income Ranking
 —    -
Market Cap709.75M 
Earnings Rating
Sell
Price Range Ratio 52W %
3.16 
Earnings Date
3rd Aug 2021

Today's Price Range

6.907.32

52W Range

6.7014.93

5 Year PE Ratio Range

-5.20-4.80

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-4.00%
1 Month
-27.65%
3 Months
-10.65%
6 Months
-39.21%
1 Year
-50.71%
3 Years
-44.98%
5 Years
-30.68%
10 Years
-

TickerPriceChg.Chg.%
EPZM6.96-0.1200-1.69
AAPL148.561.76001.20
GOOG2 756.3289.75003.37
MSFT289.673.53001.23
XOM57.04-0.0700-0.12
WFC44.59-0.4400-0.98
JNJ171.791.81001.06
FB369.7918.60005.30
GE12.710.01000.08
JPM150.64-0.2900-0.19
Financial StrengthValueIndustryS&P 500US Markets
7.90
8.70
0.65
2.70
-20.40
Leverage Ratio 3.70
ProfitabilityValueIndustryS&P 500US Markets
66.90
-1 085.40
-1 063.80
-1 095.40
-
RevenueValueIndustryS&P 500US Markets
19.57M
0.19
6.14
43.35
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.56-0.69-23.21
Q04 2020-0.59-0.65-10.17
Q03 2020-0.61-0.559.84
Q02 2020-0.56-0.58-3.57
Q01 2020-0.74-0.5131.08
Q04 2019-0.51-0.59-15.69
Q03 2019-0.54-0.4025.93
Q02 2019-0.53-0.530.00
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.60-5.26Negative
9/2021 QR-0.57-5.56Negative
12/2021 FY-2.42-9.01Negative
12/2022 FY-2.01-21.08Negative
Next Report Date3rd Aug 2021
Estimated EPS Next Report-0.60
Estimates Count6
EPS Growth Next 5 Years %38.00
Volume Overview
Volume495.79K
Shares Outstanding101.98M
Trades Count4.46K
Dollar Volume15.20M
Avg. Volume1.07M
Avg. Weekly Volume892.08K
Avg. Monthly Volume1.21M
Avg. Quarterly Volume996.53K

Epizyme Inc. (NASDAQ: EPZM) stock closed at 6.96 per share at the end of the most recent trading day (a -1.69% change compared to the prior day closing price) with a volume of 495.82K shares and market capitalization of 709.75M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 304 people. Epizyme Inc. CEO is Robert B. Bazemore.

The one-year performance of Epizyme Inc. stock is -50.71%, while year-to-date (YTD) performance is -35.91%. EPZM stock has a five-year performance of -30.68%. Its 52-week range is between 6.7 and 14.93, which gives EPZM stock a 52-week price range ratio of 3.16%

Epizyme Inc. currently has a PE ratio of -2.90, a price-to-book (PB) ratio of 8.51, a price-to-sale (PS) ratio of 37.52, a price to cashflow ratio of 31.10, a PEG ratio of 2.32, a ROA of -56.59%, a ROC of -68.74% and a ROE of -122.31%. The company’s profit margin is -%, its EBITDA margin is -1 063.80%, and its revenue ttm is $19.57 Million , which makes it $0.19 revenue per share.

Of the last four earnings reports from Epizyme Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.60 for the next earnings report. Epizyme Inc.’s next earnings report date is 03rd Aug 2021.

The consensus rating of Wall Street analysts for Epizyme Inc. is Moderate Buy (1.56), with a target price of $18.5, which is +165.81% compared to the current price. The earnings rating for Epizyme Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Epizyme Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Epizyme Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.28, ATR14 : 0.38, CCI20 : -86.19, Chaikin Money Flow : -0.04, MACD : -0.39, Money Flow Index : 30.37, ROC : -6.95, RSI : 32.80, STOCH (14,3) : 5.77, STOCH RSI : 0.02, UO : 45.68, Williams %R : -94.23), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Epizyme Inc. in the last 12-months were: Carl S. Goldfischer (Buy at a value of $60 350), David M. Mott (Buy at a value of $500 100), Jeffery Kutok (Sold 2 029 shares of value $17 855 ), Joseph Beaulieu (Sold 227 shares of value $2 545 ), Matthew E. Ros (Sold 3 766 shares of value $42 791 ), Paolo Tombesi (Option Excercise at a value of $0), Paolo Tombesi (Sold 1 021 shares of value $11 445 ), Robert B. Bazemore (Sold 20 287 shares of value $193 929 ), Shefali Agarwal (Sold 6 363 shares of value $77 780 ), Victoria Vakiener (Sold 1 416 shares of value $15 993 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (62.50 %)
6 (66.67 %)
7 (77.78 %)
Moderate Buy
1 (12.50 %)
1 (11.11 %)
1 (11.11 %)
Hold
2 (25.00 %)
2 (22.22 %)
1 (11.11 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.56
Strong Buy
1.50
Strong Buy
1.28

Epizyme Inc.

Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing and commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL), Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias and PRMT5 inhibitor.

CEO: Robert B. Bazemore

Telephone: +1 617 229-5872

Address: 400 Technology Square, Cambridge 02139, MA, US

Number of employees: 304

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

25%75%

Bearish Bullish

41%59%

Bearish Bullish

48%52%

News

Stocktwits